Skip to content

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Scientific Test of MYMD-1 as a Therapy for Delaying Aging and Expanding Healthy Life-span

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Business”), a medical phase pharmaceutical firm dedicated to extending healthy life expectancy, today introduced that the initial client has actually been enlisted in the Business’s Stage 2 medical test of lead candidate MYMD-1, an oral immune regulator medication, as a treatment for postponing aging and also broadening healthy and balanced lifespan.

The main endpoint for the Phase 2 double-blind, placebo-controlled clinical test is to achieve a reduction in the flowing levels of (TNF-α), growth necrosis element receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the proteins in the body that create inflammation and also aid trigger the procedure of aging. The additional steps of the test will certainly be the safety and security, tolerability, and also pharmacokinetics in this populace of clients.

” In a Stage 1 clinical test of MYMD-1, we showed the medication’s statistically significant efficiency in lowering degrees of TNF-α, a key player in creating pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the key endpoint for our Stage 2 research, which our company believe placements us well for a successful Phase 2 outcome,” stated Chris Chapman, M.D., President, Supervisor as well as Principal Medical Policeman of MyMD. “The initiation of patient registration in this research developments our mission to slow down the aging process, protect against loss of muscle cells in aging, limit frailty, as well as extend healthy lifespan.”

MyMD has mentioned that there are no FDA-approved drugs for treating aging disorders and expanding healthy and balanced lifespan human beings, a market expected to be at the very least $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are the most recommended medications by profits, an international market of approximately $40 billion per year,2 and, according to Nature Aging journal,3 a downturn in aging that would raise life expectancy by one year deserves $38 trillion as well as by one decade is worth $367 trillion.

Along with aging, MYMD-1’s distinct action in regulating the body immune system and treating chronic inflammation is being established for the therapy of autoimmune condition, consisting of rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetes, as well as inflammatory digestive tract illness.

” We plan to start creating procedures for a Stage 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The increasing frequency of rheumatoid arthritis and various other autoimmune and also inflammatory conditions are driving need for TNF inhibitors like MYMD-1, as well as we believe our by mouth provided medicine with really low poisoning would certainly be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”

Rheumatoid arthritis influences approximately 40 million people worldwide.4.

Concerning MYMD-1.

Initially created for autoimmune diseases, MYMD-1’s primary purpose is to slow the aging process, avoid sarcopenia and also frailty, and expand healthy and balanced life-span. Due to the fact that it can cross the blood-brain barrier and also access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related problems. Its mechanism of action and also efficacy in conditions including numerous sclerosis (MS) and also thyroiditis have been researched through collaborations with a number of academic organizations. MYMD-1 is likewise showing pledge in pre-clinical studies as a prospective treatment for message- COVID-19 complications and as an anti-fibrotic as well as anti-proliferation therapeutic.

MYMD-1 has actually revealed performance in pre-clinical research studies in managing the immune system by doing as a discerning inhibitor of growth necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike other treatments, MYMD-1 has actually been shown in these pre-clinical researches to uniquely obstruct TNF-α when it ends up being overactivated in autoimmune conditions and cytokine tornados, yet not obstruct it from doing its typical task of being a very first responder to any routine kind of modest infection. MYMD-1’s ease of dental dosing is another differentiator compared to presently available TNF-α blockers, all of which call for delivery by injection or mixture. No approved TNF inhibitor has ever been dosed by mouth. In addition, the medicine is not immunosuppressive as well as has not been shown to create the major side effects typical with typical therapies that treat swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy and balanced life expectancy, is concentrated on establishing 2 unique healing platforms that treat the reasons for disease rather than just resolving the signs and symptoms. MYMD-1 is a medicine platform based on a scientific phase small molecule that manages the immune system to regulate TNF-α, which drives chronic inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, boost long life, as well as deal with autoimmune conditions and also COVID-19- linked anxiety. The Company’s second medicine system, Supera-CBD, is being established to deal with persistent pain, dependency and also epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) and also is being developed to address as well as surpass the swiftly expanding CBD market, which includes both FDA accepted medications and also CBD products not presently regulated as drugs. For more information, see www.mymd.com.